Listen: Pharma’s telehealth gold mine, the return of the biotech IPO, & a merger deferred

Is online prescribing a good idea? When is $2 billion not a lot of money? And what’s going to happen at J.P. Morgan 2023?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Katie Palmer joins us to explain a burgeoning trend in pharmaceutical advertising that has health policy experts alarmed. We also discuss the White House’s investment in biotech, a bellwether IPO, and the latest twist in the Merck-Seagen saga.

For more on what we cover, here’s the story on telehealth prescribing; here’s the news on the White House initiative; here’s the latest on Amgen’s cancer treatment; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s our complete coverage of the Covid-19 pandemic.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].